A new paper published in Nature on June 4 shines light on how an enigmatic part of male aging—the loss of Y chromosomes—is ...

Startup Clairity scored a green light from the FDA for the agency's first artificial intelligence tool designed to predict ...

Sibeprenlimab targets a protein called A proliferation-inducing ligand (APRIL), and the drug is designed to limit the ...

Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering ...

TegMine has identified Taiwan’s OBI as a company that can help advance its ambitions. The new deal secures TegMine the right ...

In return for the ex-China rights to its new addition, called velinotamig, Cullinan has agreed to pay Genrix Bio the upfront ...

Protara, hoping to ultimately transition to a commercial stage company, snagged a chief commercial officer in Bill Conkling, ...

We hoped industry layoffs would relent in 2024. That's not what happened. Overall, biopharma layoffs rose 3% last year compared to 2023, according to an analysis of yearly data. So, here we are ...

The widely used cough suppressant dextromethorphan is an NMDA receptor antagonist. Seyltx and Atlanta-based NeurOp are ...

As favor in the general market swings away from cell therapy, Immatics’ CEO is choosing to focus on what he can control: ...

RegenXBio has shared updated phase 1/2 data on its Duchenne muscular dystrophy (DMD) gene therapy, providing evidence that ...

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...